# US 12,006,550 B2 · Targeting treatment for ADAM30 in pathological cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,550 B2
- Document ID: US12006550B2
- Status: Granted
- Kind: B2
- Application number: 17/400,308
- Filed: 2021-08-12
- Published: 2022-04-14
- Granted: 2024-06-11
- Earliest claimed: 2020-10-12
- Assignees: University of South Carolina
- Applicants: University of South Carolina
- Inventors: Wenbin Tan; Elaine G. Taine; Hui Wang; Vi Nguyen; Xiaoling Cao
- Web page: https://patentgrep.com/patent/US12006550B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are methods and systems using ADAM30 as a biomarker to help early diagnosis of congenital malformed vasculatures in children and which can also serve as a companion diagnostic biomarker for malformed vasculatures, as well as a subpopulation of cancer cells, wherein blockage of activity of ADAM30 by a neutralized antibody or inhibitor can be used as a treatment strategy for those ADAM30-positive vascular endothelial cells and cancer cells.

## Claims

### Claim 1

Methods for detecting congenital vascular malformations comprising:
obtaining at least one body fluid sample from a subject;
introducing at least one human or humanized antibody having at least two binding specificities for at least two different antigens to the at least one body fluid sample wherein the at least one human or humanized antibody compound is configured to bind to at least one domain of at least one biomarker comprising an ADAM30 protein or polypeptide thereof present in the at least one body fluid sample;
wherein binding of the at least one human or humanized antibody to the at least one domain of the at least one biomarker forms an assay;
wherein the presence of the at least one biomarker in the body fluid, whether analyzed in vivo or in vitro, indicates a vascular disease or disorder associated with aberrant ADAM30 expression or activity in the subject; and
wherein formation of the assay determines when there is an increase in ADAM30 to administer a therapeutically effective amount of a therapeutic agent to treat the vascular disease or disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biomarker has a genetic sequence of SEQ. ID. NO.: 1.

### Claim 3 (depends on 1)

The method of claim 1, further comprising identifying Sturge-Weber syndrome via the presence of the at least one biomarker.

### Claim 4 (depends on 1)

The method of claim 1, further comprising differentiating cancer cell subtypes via the presence of the at least one biomarker.